Sharon L. Aukerman

3.0k total citations
51 papers, 2.6k citations indexed

About

Sharon L. Aukerman is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Sharon L. Aukerman has authored 51 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 15 papers in Oncology and 11 papers in Immunology. Recurrent topics in Sharon L. Aukerman's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Fibroblast Growth Factor Research (6 papers) and Virus-based gene therapy research (5 papers). Sharon L. Aukerman is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Fibroblast Growth Factor Research (6 papers) and Virus-based gene therapy research (5 papers). Sharon L. Aukerman collaborates with scholars based in United States, Poland and Australia. Sharon L. Aukerman's co-authors include Glenn F. Pierce, Janet E. Price, Carla Heise, Evelyn N. Garrett, W Wiktor-Jędrzejczak, Isaiah J. Fidler, Charles F. Morris, Paul W. Hollenbach, Helen Brady and Aaron Nguyen and has published in prestigious journals such as Journal of Clinical Investigation, Blood and PLoS ONE.

In The Last Decade

Sharon L. Aukerman

51 papers receiving 2.5k citations

Peers

Countries citing papers authored by Sharon L. Aukerman

Since Specialization

Citations

This map shows the geographic impact of Sharon L. Aukerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon L. Aukerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon L. Aukerman more than expected).

Fields of papers citing papers by Sharon L. Aukerman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon L. Aukerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon L. Aukerman. The network helps show where Sharon L. Aukerman may publish in the future.

Co-authorship network of co-authors of Sharon L. Aukerman

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon L. Aukerman. A scholar is included among the top collaborators of Sharon L. Aukerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon L. Aukerman. Sharon L. Aukerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. II. Amrubicin Shows Metabolic Advantages over Doxorubicin and Epirubicin	Journal of Pharmacology and Experimental Therapeutics	Emanuela Salvatorelli, Pierantonio Menna et al.	28
2	Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. I. Amrubicin Accumulates to a Lower Level than Doxorubicin or Epirubicin	Journal of Pharmacology and Experimental Therapeutics	Emanuela Salvatorelli, Pierantonio Menna et al.	9
3	Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells	Cancer Chemotherapy and Pharmacology	Vidya Mamidipudi, Tao Shi et al.	8
4	A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines	PLoS ONE	Paul W. Hollenbach, Aaron Nguyen et al.	288
5	Recombinant Interleukin-2 Significantly Augments Activity of Rituximab in Human Tumor Xenograft Models of B-cell Non-Hodgkin Lymphoma	Journal of Immunotherapy	Daniel E. Lopes de Menezes, Kimberly Denis-Mize et al.	22
6	Matrix Immobilization Enhances the Tissue Repair Activity of Growth Factor Gene Therapy Vectors	Human Gene Therapy	John A. Doukas, Lois A. Chandler et al.	80
7	Fibroblast Growth Factor 2-Retargeted Adenoviral Vectors Exhibit a Modified Biolocalization Pattern and Display Reduced Toxicity Relative to Native Adenoviral Vectors	Human Gene Therapy	Marie A. Printz, Ana María González et al.	47
8	Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice.	PubMed	Marie A. Printz, Wenbin Ying et al.	85
9	Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines	International Journal of Cancer	Lois A. Chandler, Barbara A. Sosnowski et al.	71
10	Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficientop/op mouse: Evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma	International Journal of Cancer	Andrzej Nowicki, Andrzej Wójtowicz et al.	96
11	Keratinocyte growth factor induces proliferation of hepatocytes and epithelial cells throughout the rat gastrointestinal tract.	Journal of Clinical Investigation	Charles F. Morris, Barbara J. Ring et al.	242
12	The skeletal effects of colony-stimulating factor-1 in toothless (osteopetrotic) rats: Persistent metaphyseal sclerosis and the failure to restore subepiphyseal osteoclasts	Bone	Sandy C. Marks, Carole A. MacKay et al.	42
13	Macrophage colony‐stimulating factor induces indirect angiogenesis in vivo	Wound Repair and Regeneration	Gregg D. Phillips, Sharon L. Aukerman et al.	6
14	The effects of colony-stimulating factor-1 on tooth eruption in the toothless (osteopetrotic) rat in relation to the critical periods for bone resorption during tooth eruption	Archives of Oral Biology	Sharon L. Aukerman, Sandy C. Marks et al.	60
15	Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor.	PubMed	W Wiktor-Jędrzejczak, Elżbieta Urbanowska et al.	161
16	Colony-Stimulating Factor-1 and c-fmsExpression in Human Endometrial Tissues and Placenta during the Menstrual Cycle and Early Pregnancy*	The Journal of Clinical Endocrinology & Metabolism	Scott W. Kauma, Sharon L. Aukerman et al.	83
17	Anti‐tumor effects of recombinant human macrophage colony‐stimulating factor, alone or in combination with local irradiation, in mice inoculated with lewis lung carcinoma cells	International Journal of Cancer	Rong‐Nian Shen, Zhonghua Lin et al.	21
18	Contrast-enhanced magnetic resonance imaging of tumor-bearing mice treated with human recombinant tumor necrosis factor alpha.	PubMed	Klaus P. Aicher, David L. White et al.	44
19	Thein vitro invasiveness and interactions with laminin of K-1735 melanoma cells. Evidence for different laminin-binding affinities in high and low metastatic variants	Clinical & Experimental Metastasis	Adriana Albini, Sharon L. Aukerman et al.	30
20	Metastatic potential of cloned murine melanoma cells transfected with activated c-Ha-ras.	PubMed	Janet E. Price, Sharon L. Aukerman et al.	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact